<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>LSE:GSK on 无关紧要的宇宙</title><link>https://316140221.github.io/Hugo/zh/tags/lsegsk/</link><description>Recent content in LSE:GSK on 无关紧要的宇宙</description><generator>Hugo</generator><language>zh-CN</language><lastBuildDate>Fri, 08 Aug 2025 07:27:07 +0800</lastBuildDate><atom:link href="https://316140221.github.io/Hugo/zh/tags/lsegsk/index.xml" rel="self" type="application/rss+xml"/><item><title>GSK Set for $500 Million Payment From mRNA Lawsuit Settlement</title><link>https://316140221.github.io/Hugo/zh/en/finance/2025-08-08-gsk-set-for-500-million-payment-from-mrna-lawsuit-/</link><pubDate>Fri, 08 Aug 2025 07:27:07 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/en/finance/2025-08-08-gsk-set-for-500-million-payment-from-mrna-lawsuit-/</guid><description>CureVac NV has settled a long-running patent dispute over mRNA vaccines with Pfizer Inc. and BioNTech SE in the US, which will see CureVac’s former collaborator GSK Plc receive as much as $500 million</description></item><item><title>GSK Set for $500 Million Payment From mRNA Lawsuit Settlement</title><link>https://316140221.github.io/Hugo/zh/zh/finance/2025-08-08-gsk-set-for-500-million-payment-from-mrna-lawsuit-/</link><pubDate>Fri, 08 Aug 2025 07:27:07 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/zh/finance/2025-08-08-gsk-set-for-500-million-payment-from-mrna-lawsuit-/</guid><description>CureVac NV has settled a long-running patent dispute over mRNA vaccines with Pfizer Inc. and BioNTech SE in the US, which will see CureVac’s former collaborator GSK Plc receive as much as $500 million</description></item><item><title>Hengrui Shares Jump on GSK Deal Worth Up To $12 Billion</title><link>https://316140221.github.io/Hugo/zh/en/finance/2025-07-28-hengrui-shares-jump-on-gsk-deal-worth-up-to-12-bil/</link><pubDate>Mon, 28 Jul 2025 02:54:34 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/en/finance/2025-07-28-hengrui-shares-jump-on-gsk-deal-worth-up-to-12-bil/</guid><description>Jiangsu Hengrui Pharmaceuticals Co. shares rallied to their highest levels in four years after GSK Plc agreed to pay $500 million upfront for the company’s potential chronic lung disease treatment.</description></item><item><title>Hengrui Shares Jump on GSK Deal Worth Up To $12 Billion</title><link>https://316140221.github.io/Hugo/zh/zh/finance/2025-07-28-hengrui-shares-jump-on-gsk-deal-worth-up-to-12-bil/</link><pubDate>Mon, 28 Jul 2025 02:54:34 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/zh/finance/2025-07-28-hengrui-shares-jump-on-gsk-deal-worth-up-to-12-bil/</guid><description>Jiangsu Hengrui Pharmaceuticals Co. shares rallied to their highest levels in four years after GSK Plc agreed to pay $500 million upfront for the company’s potential chronic lung disease treatment.</description></item></channel></rss>